Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
When it comes to treating pyelonephritis, newer antibiotics don't necessarily mean better outcomes. A multicenter study of over 1,100 ED patients found no significant difference in 14-day treatment failure rates across first-, second-, and third-generation oral cephalosporins. The findings suggest that antibiotic selection should be tailored to individual patient factors and local resistance patterns rather than defaulting to newer agents.
When it comes to treating kidney infections in the ER, newer antibiotics don't necessarily mean better outcomes. A multicenter retrospective study across 11 US academic emergency departments found that patients discharged with acute pyelonephritis had similar 14-day treatment failure rates regardless of whether they received first-, second-, or third-generation oral cephalosporins. The results challenge the assumption that escalating to newer antibiotic generations automatically improves outcomes.
The study did highlight one important nuance: patients with cefazolin-resistant bacterial isolates fared significantly worse, with a 71.1% treatment failure rate compared to just 17.5% in those with susceptible isolates. This underscores the critical role of urine culture results and resistance profiling in guiding antibiotic choices.
By the Numbers:
Why it matters: These findings push back against reflexive antibiotic escalation and support a more personalized approach — factoring in resistance risk, patient characteristics, and side effect profiles — to optimize pyelonephritis treatment right from the ED.
